Overview
Rallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024
Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024
Co sells REV102 interest for up to $25 mln, extending cash runway
Outlook
Rallybio expects RLYB116 study data in 3Q and 4Q 2025
Company's cash runway extended into mid-2027 after REV102 sale
Rallybio anticipates complete complement inhibition in RLYB116 study
Company focuses RLYB116 on PTR and APS conditions
Result Drivers
REVENUE DECLINE - Decrease in revenue attributed to changes in collaboration agreements with Johnson & Johnson
R&D EXPENSES DROP - Lower R&D expenses due to decreased development costs for RLYB212 and other programs
CASH INFUSION - Sale of REV102 interest to Recursion Pharmaceuticals extends cash runway into mid-2027
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | -$9.70 mln | ||
Q2 Basic EPS | -$0.22 | ||
Q2 Income From Operations | -$10.06 mln | ||
Q2 Operating Expenses | $10.27 mln |
Press Release: ID:nBw38yYrla
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.